Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Mar;111(3):906–912. doi: 10.1111/j.1476-5381.1994.tb14824.x

Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.

S M Yu 1, T S Wu 1, C M Teng 1
PMCID: PMC1910103  PMID: 8019768

Abstract

1. The pharmacological effects of cinnamophilin, a new lignan, isolated from Cinnamomum philippinense, was determined in vitro in human platelet, rat isolated aorta and guinea-pig isolated trachea and in vivo in mice and guinea-pigs. 2. Cinnamophilin inhibited dose-dependently human platelet-rich plasma (PRP) aggregation induced by arachidonic acid (AA), collagen and U-46619 with IC50 of 5.0 +/- 0.4, 5.6 +/- 0.6 and 3.0 +/- 0.4 microM, respectively. The second wave of ADP- or adrenaline-induced platelet aggregation was inhibited by cinnamophilin, while the first wave was only slightly inhibited by cinnamophilin above 30 microM. 3. Cinnamophilin was found to be a thromboxane A2 (TXA2) receptor blocking agent in human platelet, rat aorta and guinea-pig trachea as revealed by its competitive antagonism of U-46619-induced aggregation of human-PRP, contraction of rat aortic rings and guinea-pig tracheal rings with pA2 values of 7.3 +/- 0.2, 6.3 +/- 0.1 and 5.2 +/- 0.2, respectively. 4. [3H]-inositol monophosphate formation and the rise of intracellular Ca2+ caused by U-46619 in human platelet was suppressed by cinnamophilin (10 microM). 5. Cinnamophilin induced a dose-dependent inhibition of thromboxane B2 (TXB2) formation, while the prostaglandin E2 (PGE2) formation was increased. Cinnamophilin did not affect unstimulated platelet adenosine 3':5'-cyclic monophosphate (cyclic AMP) levels. When the platelets were challenged with AA, a dose-dependent rise in cyclic AMP was observed. Dazoxiben (a pure TX synthase inhibitor) and SQ 29548 (a pure TXA2 receptor antagonist) did not affect cyclic AMP levels in AA-treated platelets.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
906

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avdonin P. V., Svitina-Ulitina I. V., Leytin V. L., Tkachuk V. A. Interaction of stable prostaglandin endoperoxide analogs U46619 and U44069 with human platelet membranes: coupling of receptors with high-affinity GTPase and adenylate cyclase. Thromb Res. 1985 Oct 1;40(1):101–112. doi: 10.1016/0049-3848(85)90354-8. [DOI] [PubMed] [Google Scholar]
  2. Bartele V., Cerletti C., Schiepatti A., di Minno G., de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet. 1981 May 9;1(8228):1057–1058. doi: 10.1016/s0140-6736(81)92224-8. [DOI] [PubMed] [Google Scholar]
  3. De Clerck F., Beetens J., Van de Water A., Vercammen E., Janssen P. A. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thromb Haemost. 1989 Feb 28;61(1):43–49. [PubMed] [Google Scholar]
  4. FitzGerald G. A., Reilly I. A., Pedersen A. K. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation. 1985 Dec;72(6):1194–1201. doi: 10.1161/01.cir.72.6.1194. [DOI] [PubMed] [Google Scholar]
  5. Greenberg R., Steinbacher T. E., Harris D. N., Haslanger M. F. Thromboxane receptor antagonist properties of SQ 27,427 in the anesthetized guinea pig. Eur J Pharmacol. 1984 Aug 3;103(1-2):19–24. doi: 10.1016/0014-2999(84)90184-5. [DOI] [PubMed] [Google Scholar]
  6. Gresele P., Arnout J., Deckmyn H., Huybrechts E., Pieters G., Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest. 1987 Nov;80(5):1435–1445. doi: 10.1172/JCI113223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gresele P., Blockmans D., Deckmyn H., Vermylen J. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. J Pharmacol Exp Ther. 1988 Jul;246(1):301–307. [PubMed] [Google Scholar]
  8. Gresele P., Corona C., Alberti P., Nenci G. G. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb Haemost. 1990 Aug 13;64(1):80–86. [PubMed] [Google Scholar]
  9. Gresele P., Deckmyn H., Arnout J., Lemmens J., Janssens W., Vermylen J. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet. 1984 May 5;1(8384):991–994. doi: 10.1016/s0140-6736(84)92328-6. [DOI] [PubMed] [Google Scholar]
  10. Gresele P., Deckmyn H., Arnout J., Nenci G. G., Vermylen J. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemost. 1989 Jun 30;61(3):479–484. [PubMed] [Google Scholar]
  11. Gresele P., Deckmyn H., Nenci G. G., Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci. 1991 Apr;12(4):158–163. doi: 10.1016/0165-6147(91)90533-x. [DOI] [PubMed] [Google Scholar]
  12. Gryglewski R. J., Bunting S., Moncada S., Flower R. J., Vane J. R. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins. 1976 Nov;12(5):685–713. doi: 10.1016/0090-6980(76)90047-2. [DOI] [PubMed] [Google Scholar]
  13. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hoet B., Falcon C., De Reys S., Arnout J., Deckmyn H., Vermylen J. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood. 1990 Feb 1;75(3):646–653. [PubMed] [Google Scholar]
  15. Hornstra G., Christ-Hazelhof E., Haddeman E., ten Hoor F., Nugteren D. H. Fish oil feeding lowers thromboxane- and prostacyclin production by rat platelets and aorta and does not result in the formation of prostaglandin I3. Prostaglandins. 1981 May;21(5):727–738. doi: 10.1016/0090-6980(81)90230-6. [DOI] [PubMed] [Google Scholar]
  16. Huang E. M., Detwiler T. C. The effects of lithium on platelet phosphoinositide metabolism. Biochem J. 1986 Jun 15;236(3):895–901. doi: 10.1042/bj2360895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol. 1978 May;30(5):312–313. doi: 10.1111/j.2042-7158.1978.tb13237.x. [DOI] [PubMed] [Google Scholar]
  18. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  19. Moncada S., Vane J. R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978 Sep;30(3):293–331. [PubMed] [Google Scholar]
  20. Moncada S., Vane J. R. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull. 1978 May;34(2):129–135. doi: 10.1093/oxfordjournals.bmb.a071482. [DOI] [PubMed] [Google Scholar]
  21. Neylon C. B., Summers R. J. Stimulation of alpha 1-adrenoceptors in rat kidney mediates increased inositol phospholipid hydrolysis. Br J Pharmacol. 1987 Jun;91(2):367–376. doi: 10.1111/j.1476-5381.1987.tb10291.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pretolani M., Lefort J., Malanchère E., Vargaftig B. B. Interference by the novel PAF-acether antagonist WEB 2086 with the bronchopulmonary responses to PAF-acether and to active and passive anaphylactic shock in guinea-pigs. Eur J Pharmacol. 1987 Aug 21;140(3):311–321. doi: 10.1016/0014-2999(87)90288-3. [DOI] [PubMed] [Google Scholar]
  23. Rink T. J., Sanchez A., Hallam T. J. Diacylglycerol and phorbol ester stimulate secretion without raising cytoplasmic free calcium in human platelets. Nature. 1983 Sep 22;305(5932):317–319. doi: 10.1038/305317a0. [DOI] [PubMed] [Google Scholar]
  24. Vargaftig B. B., Hai N. D. Selective inhibition by mepacrine of the release of "rabbit aorta contracting substance" evoked by the administration of bradykinin. J Pharm Pharmacol. 1972 Feb;24(2):159–161. doi: 10.1111/j.2042-7158.1972.tb08953.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES